Print

PharmaVOICE Names Four inVentiv Health (VTIV) Associates Among "100 Most Inspiring" Leaders in Healthcare  
8/8/2012 12:02:33 PM

BURLINGTON, Mass., Aug. 7, 2012 /PRNewswire/ -- inVentiv Health, Inc., offering best-in-class clinical, commercial and consulting services to the healthcare industry, announced today that leaders from four inVentiv Health companies were included in PharmaVOICE's 2012 list of the "100 Most Inspiring People" in the life sciences industry. inVentiv honorees include Marianne Eisenmann, Kelly Gratz, Leigh Householder and Todd LaRoche.

Every year, the July/August issue of PharmaVOICE features 100 of the "most inspiring individuals" in the life sciences industry as determined by the publication's readers. Their personal accounts detail how these 100 individuals executives, peers, colleagues, clients, partners and others contribute significantly to their organizations, while motivating and mentoring those around them.

"We congratulate Marianne, Kelly, Leigh, and Todd on this prestigious recognition," said Paul Meister, CEO of inVentiv Health. "All four of them serve as role models to the entire inVentiv organization, inspiring us to question conventional thinking and push the envelope to seek better solutions for our clients. In an industry characterized by increasing complexity and a constant demand for innovation, having strong leaders with a passion for healthcare and a commitment to client service is critical."

The honorees represent four of inVentiv's best-in-class businesses. Marianne Eisenmann leads Determinus, the research division of Chandler Chicco Companies. An advocate of communications research, Eisenmann has a proven track record in providing leading global companies with strategic support for public relations program planning and measurement.

Kelly Gratz is President of inVentiv Health Commercial Solutions, which drives the development of unique global commercial solutions for inVentiv's clients that cross traditional functional boundaries. Since joining the company in 2000, she has held senior leadership roles in inVentiv's Commercial and Communications divisions, and has been directly involved in leading the delivery of integrated solutions and multi-channel success for a number of top pharmaceutical companies.

Leigh Householder, Vice President/Managing Director of iQ, the innovation lab of GSW Worldwide, has more than 13 years of experience creating digital strategies for Fortune 1000 companies and developing social media approaches in highly-regulated industries. At GSW, she leverages that experience to develop clear points of view on how technology can change healthcare marketing.

Todd LaRoche is Executive Vice President/Managing Director of Creative at Palio. With more than 30 years of advertising and marketing communications experience, he directs creative execution from concept development through final production in all media for both professional and patient audiences.

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to companies seeking to accelerate performance. inVentiv's client roster includes more than 550 pharmaceutical, biotech and life sciences companies. With 13,000 employees in 40 countries, inVentiv rapidly transforms promising ideas into commercial reality. inVentiv Health Inc. is privately owned by inVentiv Group Holdings Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. For more information, visit http://www.inventivhealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of the consummation of any announced and future acquisitions; the impact of any additional leverage we may incur in connection with the financing of acquisitions, on our ratings and the ratings of our debt securities; our ability to sufficiently increase our revenues and maintain or decrease expenses and cash capital expenditures to permit us to fund our operations; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers from future healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and the resulting synergies; the resolution of purchase price adjustment disputes in connection with our recent acquisitions and related impacts; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base; our ability to comply with all applicable laws as well as our ability to successfully implement from a timing and cost perspective any changes in applicable laws; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the possibility that client agreements will be terminated or not renewed; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; the impact of customer project delays and cancellations; our ability to convert backlog into revenue; the potential liability associated with bringing new drugs to market, including potential liability from injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memorandums provided in connection with the issuance of our senior secured notes for further discussion of these risks and other factors.

SOURCE inVentiv Health, Inc.


//-->